Australia markets open in 4 hours 13 minutes

Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
25.900-1.050 (-3.90%)
At close: 03:54PM HKT

Zylox-Tonbridge Medical Technology Co., Ltd.

Building 1
1st and 2nd Floors No. 18 Keji Avenue Yuhang District
Hangzhou 311121
86 571 8861 0082

Sector(s):Β Healthcare
Industry:Β Medical Devices
Full-time employees:Β 361

Key executives

NameTitlePayExercisedYear born
Dr. Zhong ZhaoChairman & CEO278.59kN/A1967
Mr. Yang XieSr. VP & Exec. Director210.98kN/A1970
Dr. Zheng LiSr. VP & Exec. Director218.34kN/A1978
Mr. Quanwei YuanCFO & Joint Company Sec.N/AN/A1979
Dr. Ning PanSr. VPN/AN/A1967
Mr. Kai Cheong Cheung ACCA, CPA, FCCA, FCPAJoint Company Sec.N/AN/A1975
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.


Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices China. It primarily offers Thrombite Clot Retriever Device, a minimally invasive device to capture and remove the clot blocking blood vessels to treat neurovascular diseases such as acute ischemic stroke; and Ultrafree Drug Coated PTA Balloon Catheter, an interventional device for percutaneous transluminal angioplasty for patients with stenosis or occlusion in femoral artery and popliteal artery. The company also provides neurovascular embolization coils used in the endovascular coiling procedure; flow diverters for endovascular treatment of intracranial aneurysms; retrievable inferior vena cava filters that are placed into the inferior vena cava to prevent pulmonary embolism; peripheral venous stent system for the treatment of iliac vein stenosis or occlusive disease; and suture-mediated closure system used to suture the femoral artery access site after diagnostic/therapeutic interventional procedures. Zylox-Tonbridge Medical Technology Co., Ltd. was founded in 2012 and is headquartered in Zhejiang, the People's Republic of China.

Corporate governance

Zylox-Tonbridge Medical Technology Co., Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.